Introduction to Europe Emerging Infectious Disease Diagnostics Market
The Europe emerging infectious disease diagnostics market was valued at $4.70 billion in 2023 and is expected to reach $7.85 billion by 2033, growing at a CAGR of 5.28% between 2023 and 2033. The market for diagnosing emerging infectious diseases is experiencing growth due to several key factors. These factors encompass the economic impact of infectious diseases, financial support from governments through funding and partnerships, rising demand for point-of-care and syndromic testing, and advancements in molecular diagnostics technology.

Market Introduction
The European emerging infectious disease diagnostics market is characterized by a diverse array of methods and techniques aimed at identifying and detecting infectious agents swiftly and accurately. This sector plays a crucial role in the timely diagnosis of diseases, facilitating appropriate treatment decisions and public health responses. Within Europe, microbiological culture remains a fundamental method, involving the cultivation of patient specimens on specialized growth media to isolate and identify specific pathogens. This allows for the precise determination of the causative organism and an assessment of its susceptibility to antimicrobial agents. In addition, molecular diagnostics, a rapidly evolving field, is gaining prominence. Techniques like polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs) are extensively employed, offering highly sensitive and specific pathogen identification, even at low concentrations. With ongoing technological advancements and a growing emphasis on public health, the European market for emerging infectious disease diagnostics is poised for continuous development and innovation.

Market Segmentation:

Segmentation 1: by Application

  • Laboratory Testing
  • Point-of-Care Testing



Segmentation 2: by Technology

  • Polymerase Chain Reaction (PCR)
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • Next-Generation Sequencing (NGS)
  • Immunodiagnostics
  • Other Technologies



Segmentation 3: by Type of Infection

  • Bacterial
  • Viral
  • Fungal
  • Other Infections



Segmentation 4: by Disease Type

  • Respiratory Infections
  • Sexually Transmitted Infections (STIs)
  • Gastrointestinal Infections
  • Other Infections



Segmentation 5: by End User

  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Other End Users



Segmentation 6: by Country

  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest-of-Europe



How Can This Report Add Value to an Organization?
Product/Innovation Strategy: The Europe emerging infectious disease diagnostics market has been extensively segmented on the basis of various categories, such as application, technology, type of infection, disease type, end user, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: The Europe emerging infectious disease diagnostics market is fragmented, with several established as well as emerging players. Key players in the Europe emerging infectious disease diagnostics market analyzed and profiled in the study involve established players that offer various kinds of molecular diagnostic tests for infectious diseases.

Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.

Some of the prominent names in this market are:

  • bioM?rieux S.A
  • DiaSorin S.p.A
  • F. Hoffmann-La Roche Ltd
  • QIAGEN N.V.
  • Tecan Trading AG
  • Siemens Healthineers AG


This report will be delivered in 1-5 working days.